We are testing a modified dosing strategy of osimertinib, with or without a booster drug, for patients with advanced EGFR mutated NSCLC. This study aims to improve treatment cost-effectiveness and reduce side effects while maintaining effectiveness.
Health conditions and diseases that the clinical trial is designed to study and treat.
Non-Small Cell Lung Cancer (NSCLC) with an EGFR driver mutation is a type of lung cancer that occurs when there are mutations in the EGFR gene, leading to uncontrolled cell growth in the lungs. This condition often requires targeted treatments that focus on the specific mutation.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.